Agroz Inc. - Class A Ordinary Shares (AGRZ)

September 10, 2026 VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting one of pharmaceutical development's most expensive challenges: identifying drug toxicity before a candidate reaches human clinical trials. Using its NAMkind™ 3D human liver and intestinal models combined with AI-powered predictive toxicology, VivoSim is developing tools designed to help pharmaceutical companies determine which drug candidates should advance, be modified or be discontinued earlier .